Journal article
Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors
DM Ross, C Arthur, K Burbury, BS Ko, AK Mills, J Shortt, K Kostner
Internal Medicine Journal | WILEY | Published : 2018
DOI: 10.1111/imj.13716
Abstract
Several BCR-ABL1 tyrosine kinase inhibitors (TKIs) are approved for the first-line treatment of chronic phase chronic myeloid leukaemia (CML). Disease control is achieved in the vast majority of patients and disease-specific survival is excellent. Consequently, there is now emphasis on managing comorbidities and minimising treatment-related toxicity. Second-generation TKIs have cardiovascular risks that are greater than with imatinib treatment, but these risks must be balanced against the superior CML responses encountered with more potent TKIs. Cardiovascular risk should be assessed at baseline using a locally validated model based on the Framingham risk equation. Clinicians involved in the..
View full abstractGrants
Funding Acknowledgements
David Ross has received research funding from Novartis and honoraria from Novartis and BMS. Chris Arthur has received research funding from Novartis, BMS and Ariad and honoraria from Novartis, STA, BMS and Pfizer. Kate Burbury has received honoraria from BMS and Novartis and research funding from Ariad. Brian Ko has received honararia from BMS, Pfizer, Novartis, Specialised Therapeutics and Boehringer Ingelheim. Anthony Mills has received honoraria from Novartis, BMS, Specialised Therapeutics and Pfizer. Jake Shortt has received research funding from BMS and honoraria from Novartis and BMS. Karam Kostner has no disclosures relevant to this publication.